Ardis final


Published on

  • Be the first to comment

  • Be the first to like this

Ardis final

  1. Advanced Retinal Diagnostic Imaging Services Alex Etlin, PhD Vickie Zhang, PhD(c) Brandon Lujan, MD Total Interviews: 101 Luke Lee, MBA
  2. Age-related Macular Degeneration (AMD)
  3. Age-related Macular Degeneration (AMD) Advanced Form
  4. Age-related Macular Degeneration (AMD) Early Form Advanced Form
  5. Age-related Macular Degeneration (AMD) Early Form Advanced Form
  6. Total Available Market $12 billion Target Market $120 million
  7. Asymptomatic individuals over age 60
  8. •Asymptomatic adults don’t care to be imaged •Most AMD patients would like to be monitored more frequently
  9. Clinical evidence showing frequent monitoring results in better patient outcomes. Clinicians don’t think they should pay for our service.
  10. To get and keep patients, “you have to provide easy access and financial support so patients don’t have to pay.” Then patients would want to show up
  11. We learned: Customer segments What do they want? Asymptomatic individuals Patients Would like to be monitored frequently Prefer easy access to care Some are willing to pay Clinicians Want to see clinical evidence Do not want to pay Who should be our payers? Insurance companies? Pharma companies?
  12. •Clinical evidence that frequent monitoring leads to better patient outcomes •Frequent monitoring would reduce overall healthcare costs! Validation: Early detection of disease progression => decrease cost of treatments CLINICAL TRIAL
  13. What does industry say?
  14. Industry: Overwhelmed by Data “We Need insight from existing clinical data” To better design what is coming next: Who to include? What endpoints?
  15. ARDIS: Value-added Analysis
  16. Where do we go from here? 1. Already submitted three analysis proposals 2. How can we build value using other’s data? 3. Perform our own trial and protect insights
  17. Pilot Clinical Data: Frequent Monitoring Matters San Francisco VA Medical Center
  18. Investment Readiness